Home The Word Brain My Amedeo FAQ Privacy About   


C49

In our changing world, speaking just English isn't enough. Open new doors with skills in another world language.

Start with 7 words a day.

Next week: +49.


  Lung Cancer

  Free Subscription


24.03.2025

1 Ann Surg Oncol
8 BMC Cancer
2 Br J Cancer
3 Cancer Lett
1 Cancer Sci
1 Clin Cancer Res
2 Clin Exp Metastasis
3 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cancer
1 Genes Chromosomes Cancer
3 Int J Radiat Oncol Biol Phys
1 J Clin Invest
2 J Clin Oncol
1 J Natl Cancer Inst
1 JAMA Oncol
1 Lancet Oncol
11 Lung Cancer
1 Nat Med
1 Oncol Rep
2 Oncologist
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Surg Oncol

  1. LAMPA E, Boros M, Berglund A, Wagenius G, et al
    Timing of Adjuvant Chemotherapy After Surgical Resection for Non-small Cell Lung Cancer: A Target Trial Emulation Using Nationwide Swedish Registry Data.
    Ann Surg Oncol. 2025 Mar 19. doi: 10.1245/s10434-025-17193.
    PubMed         Abstract available


    BMC Cancer

  2. CAO L, Li T, Xu X, Sun M, et al
    Texasin, A main product from Caragana Jubata (Pall.) Poir, induces proliferation arrest and protective autophagy in lung adenocarcinoma.
    BMC Cancer. 2025;25:513.
    PubMed         Abstract available

  3. LIU X, Yin X, Zhuang L, Wen J, et al
    Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study.
    BMC Cancer. 2025;25:509.
    PubMed         Abstract available

  4. HE D, Lu H, Ou X, Zheng T, et al
    Correction: Exposure to major coronary heart disease events reduces lung cancer risk: a Mendelian randomization study based on a European population.
    BMC Cancer. 2025;25:501.
    PubMed        

  5. LIN W, Wang Y, Li M, Feng J, et al
    Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.
    BMC Cancer. 2025;25:489.
    PubMed         Abstract available

  6. SHI Y, Wang X, Pei Z, Shi H, et al
    Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.
    BMC Cancer. 2025;25:490.
    PubMed         Abstract available

  7. LI Y, Liu Y, Xie Y, Wang Y, et al
    Long-read RNA sequencing enables full-length chimeric transcript annotation of transposable elements in lung adenocarcinoma.
    BMC Cancer. 2025;25:482.
    PubMed         Abstract available

  8. LI Y, Tong Z, Yang Y, Wang Y, et al
    Lung Cancer Biomarker Database (LCBD): a comprehensive and curated repository of lung cancer biomarkers.
    BMC Cancer. 2025;25:478.
    PubMed         Abstract available

  9. ZHAO K, Lu S, Niu J, Zhu H, et al
    Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.
    BMC Cancer. 2025;25:467.
    PubMed         Abstract available


    Br J Cancer

  10. LIN X, Liu Z, Zhou K, Li Y, et al
    Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC.
    Br J Cancer. 2025;132:558-568.
    PubMed         Abstract available

  11. ZHANG W, Wang J, Liang J, He Z, et al
    RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC.
    Br J Cancer. 2025;132:569-579.
    PubMed         Abstract available


    Cancer Lett

  12. LI J, Xu S, Zhan Y, Lv X, et al
    CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145/HK2 pathway.
    Cancer Lett. 2025 Mar 14:217639. doi: 10.1016/j.canlet.2025.217639.
    PubMed         Abstract available

  13. JIANG J, Chen H, Zhao C, Li T, et al
    PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma.
    Cancer Lett. 2025;616:217584.
    PubMed         Abstract available

  14. LIN H, Hua J, Gong Z, Chen M, et al
    Multimodal radiopathological integration for prognosis and prediction of adjuvant chemotherapy benefit in resectable lung adenocarcinoma: A multicentre study.
    Cancer Lett. 2025;616:217557.
    PubMed         Abstract available


    Cancer Sci

  15. SHEN S, Wu Y, Shao Z, Li Y, et al
    LTF as a Potential Predictive Biomarker for Durable Benefit From First-Line Chemo-Immunotherapy in Small Cell Lung Cancer.
    Cancer Sci. 2025 Mar 17. doi: 10.1111/cas.70049.
    PubMed         Abstract available


    Clin Cancer Res

  16. KATAYAMA Y, Yamada T, Tanimura K, Kawachi H, et al
    YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
    Clin Cancer Res. 2025;31:1127-1141.
    PubMed         Abstract available


    Clin Exp Metastasis

  17. YANG J, Feng J, Duan Z, Liu X, et al
    Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics.
    Clin Exp Metastasis. 2025;42:20.
    PubMed         Abstract available

  18. LIU Z, Song H, Wang Z, Hu Y, et al
    A novel optimized orthotopic mouse model for brain metastasis with sustained cerebral blood circulation and capability of multiple delivery.
    Clin Exp Metastasis. 2025;42:19.
    PubMed         Abstract available


    Clin Lung Cancer

  19. WALLACE ND, Xie J, Alexander M, Ball D, et al
    Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study.
    Clin Lung Cancer. 2025 Feb 21:S1525-7304(25)00041.
    PubMed         Abstract available

  20. WILDER FG, McAllister M, Singh A, Xie Y, et al
    Lung Cancer in Patients Under 50: What is the Role of Social Determinants of Health?
    Clin Lung Cancer. 2025 Feb 20:S1525-7304(25)00039.
    PubMed         Abstract available

  21. ZHANG Y, Zhou SH, Yan YJ, Wu LL, et al
    Predicting Severe Radiation Pneumonitis in Patients With Locally-Advanced Non-Small-Cell Lung Cancer After Thoracic Radiotherapy: Development and Validation of a Nomogram Based on the Clinical, Hematological, and Dose-Volume Histogram Parameters.
    Clin Lung Cancer. 2025 Feb 21:S1525-7304(25)00042.
    PubMed         Abstract available


    Clin Nucl Med

  22. CHENG Y, Jiang ZP, Chen XB, Lu KY, et al
    Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Resectable Non-small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy.
    Clin Nucl Med. 2025 Mar 20. doi: 10.1097/RLU.0000000000005863.
    PubMed         Abstract available


    Eur J Cancer

  23. MULSHINE JL, Avila RS, Sylva M, Aldige C, et al
    AI integrations with lung cancer screening: Considerations in developing AI in a public health setting.
    Eur J Cancer. 2025;220:115345.
    PubMed         Abstract available


    Genes Chromosomes Cancer

  24. YAA RM, Schilder BM, Acemel RD, Wardle FC, et al
    Chromatin Interaction and Histone Mark Signatures Associated With TBXT Expression in Metastatic Lung Cancer.
    Genes Chromosomes Cancer. 2025;64:e70041.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  25. HUANG YH, Li Z, Xiong T, Chen Z, et al
    Constructing Surrogate Lung Ventilation Maps From 4-Dimensional Computed Tomography-Derived Subregional Respiratory Dynamics.
    Int J Radiat Oncol Biol Phys. 2025;121:1328-1338.
    PubMed         Abstract available

  26. PAN S, Chang CW, Tian Z, Wang T, et al
    Data-Driven Volumetric Computed Tomography Image Generation From Surface Structures Using a Patient-Specific Deep Leaning Model.
    Int J Radiat Oncol Biol Phys. 2025;121:1349-1360.
    PubMed         Abstract available

  27. CHEN X, Meng F, Zhang P, Wang L, et al
    Establishing a deep learning model that integrates pre- and mid-treatment computed tomography to predict treatment response for non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2025 Mar 13:S0360-3016(25)00243.
    PubMed         Abstract available


    J Clin Invest

  28. SHEN S, Zhang Q, Wang Y, Chen H, et al
    Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.
    J Clin Invest. 2025;135:e185278.
    PubMed         Abstract available


    J Clin Oncol

  29. KONG FS, Hu C, Bradley JD, Machtay M, et al
    Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Mar 21:JCO2500069. doi: 10.1200/JCO-25-00069.
    PubMed        

  30. WU Y, Bi N
    Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.
    J Clin Oncol. 2025 Mar 21:JCO2402532. doi: 10.1200/JCO-24-02532.
    PubMed        


    J Natl Cancer Inst

  31. MILDER CM, Cahoon EK, Schonfeld SJ, Preston DL, et al
    Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiologic technologists.
    J Natl Cancer Inst. 2025 Mar 20:djaf064. doi: 10.1093.
    PubMed         Abstract available


    JAMA Oncol

  32. ROLLE LD, Olazagasti C, Lopes G, Rodriguez E, et al
    USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence.
    JAMA Oncol. 2025 Mar 20. doi: 10.1001/jamaoncol.2025.0230.
    PubMed        


    Lancet Oncol

  33. GOURD E
    Lung cancer treatment compromised by delayed genomic test results.
    Lancet Oncol. 2025 Mar 13:S1470-2045(25)00149.
    PubMed        


    Lung Cancer

  34. VAN DER WEL JWT, de Langen AJ
    Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.
    Lung Cancer. 2025 Mar 14:108490. doi: 10.1016/j.lungcan.2025.108490.
    PubMed         Abstract available

  35. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
    Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention.
    Lung Cancer. 2025;202:108500.
    PubMed         Abstract available

  36. GOTO Y, Watanabe S, Yanagimura N, Arita M, et al
    The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.
    Lung Cancer. 2025;202:108505.
    PubMed         Abstract available

  37. NAVEED F, Khan S, Khan A, Arshad F, et al
    Letter: Alectinib combined with cobimetinib in ALK-rearranged lung cancer: A phase IB study.
    Lung Cancer. 2025;202:108489.
    PubMed        

  38. VERKOULEN KCHA, Laven IEWG, Daemen JHT, Franssen AJPM, et al
    From data to prediction: Digital chest drain insights into postoperative recovery after lung cancer surgery.
    Lung Cancer. 2025;202:108486.
    PubMed         Abstract available

  39. JABER G, Raffoul C, Diab T, Sinno S, et al
    ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a Rare Case.
    Lung Cancer. 2025;202:108497.
    PubMed         Abstract available

  40. COOKE S, Nelson D, Argin AA, Laparidou D, et al
    Identifying and exploring patient engagement interventions for people diagnosed with lung cancer: A rapid systematic review.
    Lung Cancer. 2025;202:108484.
    PubMed         Abstract available

  41. NOUSIAS O, Mandell JD, Anderson KS, Townsend JP, et al
    Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.
    Lung Cancer. 2025;202:108487.
    PubMed         Abstract available

  42. UEHARA Y, Izumi H, Kobayashi IS, Matsumoto S, et al
    Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).
    Lung Cancer. 2025;202:108479.
    PubMed         Abstract available

  43. GRIDELLI C, Attili I, Bennati C, Bironzo P, et al
    Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?
    Lung Cancer. 2025;202:108482.
    PubMed         Abstract available

  44. CHO BC, Johnson M, Bar J, Schaefer E, et al
    A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
    Lung Cancer. 2025;202:108492.
    PubMed         Abstract available


    Nat Med

  45. HERBST RS, John T, Grohe C, Goldman JW, et al
    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
    Nat Med. 2025 Mar 17. doi: 10.1038/s41591-025-03577.
    PubMed         Abstract available


    Oncol Rep

  46. HU Y, Liu X, Yuan Z, He J, et al
    Induction of necroptosis in lung adenocarcinoma by miR?10b?5p through modulation of the PKP3/RIPK3/MLKL cascade.
    Oncol Rep. 2025;53:56.
    PubMed         Abstract available


    Oncologist

  47. VITALE A, Vita E, Stefani A, Cancellieri A, et al
    Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.
    Oncologist. 2025;30:oyaf030.
    PubMed         Abstract available

  48. LI Y, Li C, Zhao X, Li Y, et al
    Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial.
    Oncologist. 2025;30:oyae336.
    PubMed         Abstract available


    PLoS One

  49. HOSSAIN MS, Basak N, Mollah MA, Nahiduzzaman M, et al
    Ensemble-based multiclass lung cancer classification using hybrid CNN-SVD feature extraction and selection method.
    PLoS One. 2025;20:e0318219.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.